Trigeminal Neuralgia — Causes, Symptoms, MRI, and Treatment When Pain Persists

Author: Dr. Zeljko Kojadinovic, MD, PhD – Neurosurgeon and Pain Management Specialist

Last medically reviewed: June 10, 2026

Trigeminal neuralgia is characterized by sudden, severe, electric-shock–like facial pain that occurs when the trigeminal nerve becomes irritated or compressed. The trigeminal nerve supplies sensation to the face, oral cavity, and part of the ear.

In the early phase, the main mechanism is mechanical irritation or compression of the nerve (for example, by a blood vessel). Pain is usually triggered by light touch, speaking, chewing, or brushing teeth. Over time, repeated irritation can damage the nerve fibers and lead to neuropathic pain. The nerve becomes hypersensitive, and pain may start to appear even with minimal triggers — or without any trigger at all.

Trigeminal neuralgia can appear in several forms — typical, atypical, pre-neuralgia, post-traumatic, secondary (including MS-related), and treatment-resistant cases.

The most important first step is to determine which type is present, because treatment differs significantly between typical, atypical, and secondary trigeminal neuralgia, and each requires a different therapeutic approach.

Many patients are diagnosed simply with “trigeminal neuralgia” and are treated according to the standard protocol for typical TN, even though their pain pattern is not truly typical. If pain becomes constant, burning, post-dental, viral-related, treatment-resistant, or does not match meaningful vascular compression on MRI, the problem may not be classical trigeminal neuralgia alone. In such cases, continuing the same protocol may fail because the active pain generator has not been correctly identified.

Listen to the YouTube audio explanation on the diagnosis and treatment of refractory trigeminal neuralgia explained by the author.

Typical vs Atypical Trigeminal Neuralgia: Why the Treatment Path Differs

Trigeminal neuralgia is not one single pain mechanism. Some patients have typical trigeminal neuralgia with brief electric-shock attacks, clear trigger zones, and pain-free intervals. Others have atypical or persistent facial pain with burning, aching, post-dental pain, viral nerve injury, peripheral nerve irritation, TMJ or muscle-related factors, or central sensitization.

This distinction is important because treatments that work well for classical trigeminal neuralgia are less predictable in constant or atypical facial pain. Carbamazepine, microvascular decompression, Gamma Knife, or rhizotomy may be very effective when the pain pattern and MRI findings match classical trigeminal neuralgia. However, when pain is continuous, burning, post-traumatic, post-dental, or not supported by meaningful vascular compression on MRI, the first step is not simply choosing another procedure. The first step is identifying which trigeminal pain mechanism is actually active.

In practice, treatment decisions usually depend on four questions:

• Does the pain pattern fit typical electric-shock trigeminal neuralgia or atypical persistent facial pain?
• Does MRI show vascular compression that truly matches the clinical symptoms?
• Is the pain coming from the trigeminal nerve root, a peripheral facial branch, viral nerve injury, dental trauma, TMJ or muscle-related irritation, or central sensitization?
• Is the next step medication optimization, nerve block, Botox, Gamma Knife, rhizotomy, MVD surgery, or structured observation?

Typical trigeminal neuralgia

Image: trigeminal nerve with its three main branches across the face

Typical trigeminal neuralgia is characterized by sudden, brief, electric-shock–like attacks of severe facial pain. Each attack lasts from a few seconds up to one minute and can occur dozens or even hundreds of times per day. Between attacks, there is no pain, and the neurological examination is normal — this is one of the key diagnostic features of typical trigeminal neuralgia.

Causes of Typical Trigeminal Neuralgia (Etiology)

The most common cause of typical trigeminal neuralgia is mechanical compression of the trigeminal nerve root by a nearby artery as it exits the brainstem.
In the early stage, pain is triggered only when the nerve is stimulated — for example when speaking, chewing, brushing teeth, shaving, or touching the face.

With time, repeated compression damages the nerve fibers, making the nerve hypersensitive. A neuropathic pain component then develops, and pain may start to appear spontaneously — even without a trigger.

Who develops Typical Trigeminal Neuralgia

Typical trigeminal neuralgia most often begins after the age of 50 and is more frequent in women, and is rare in individuals under 40. The condition often has cycles: episodes of frequent attacks followed by remission lasting weeks, months, or even years.

Symptoms of Typical Trigeminal Neuralgia (Clinical Presentation)

Pain is sudden, stabbing, or electric-shock–like, usually affecting one side of the face. It may appear in the jaw, teeth, cheek, near the nose, around the eye, or deep inside the ear.
Even light stimulation — such as chewing, talking, brushing teeth, or exposure to cold wind — can trigger the attack. These highly sensitive areas on the face or in the mouth are called trigger zones.

Many patients initially assume the pain is dental in origin. They undergo fillings, root canals, or even tooth extractions — without relief, because the tooth is not the source of the pain.
Even when pain appears in different facial regions (jaw, cheek, around the eye, or in the ear), the source is the same — irritation or compression of the trigeminal nerve at the root entry zone, before it divides into individual branches.

Image: Nerves that innervate skin of the head and face Read more about the anatomy of the cranial nerves here

Image: Three facial regions where pain can occur, either separately or in combination

How Typical Trigeminal Nerve Pain Is Diagnosed

In addition to examining the patient, an MRI of the brain is required to determine whether there is a pathological process causing the neuralgia. In such cases, it is referred to as secondary trigeminal neuralgia. Possible causes include tumors, multiple sclerosis, aneurysms, dental diseases, etc.

The typical cause of trigeminal neuralgia is pressure from a blood vessel on the nerve, as shown in the image. In most cases, this can be diagnosed with a brain MRI. However, the finding of vascular contact must match the clinical picture and the response to therapy to confirm that this is truly the cause and to justify surgical treatment.

Image: Arrow shows where the artery presses on the trigeminal nerve, causing pain. The nerve arises from the brainstem and ends in the Gasserian ganglion.

How Typical Trigeminal Neuralgia Is Treated – Medications and More

Treatment always begins with medication. The first-line drug is carbamazepine (Tegretol), and most patients respond well in the early phase. If carbamazepine is not effective or causes side effects, oxcarbazepine or a combination therapy with gabapentin/pregabalin or baclofen can be introduced to improve pain control with fewer adverse effects. If pain becomes more persistent or shows a neuropathic component, tricyclic antidepressants (such as amitriptyline or nortriptyline) or SNRIs (duloxetine, venlafaxine) may be added to stabilize nerve sensitivity and enhance long-term pain control. Medication initiation, monitoring of side effects, and dose titration can be performed through an online video consultation, which is especially important during the first weeks while the effective therapeutic dose is being reached.

Not all patients react the same way to medication. In the first 1–2 weeks, dosage adjustments are often required to maintain the effect. Over time, medications may become less effective, the attacks may last longer, or pain may begin to appear between attacks. Many people interpret this as “the medication has stopped working and the next step is surgery,” but this is often not true.

For patients who want to avoid surgery, or where surgery carries a higher risk due to age or comorbidities, pain can often be successfully controlled with an optimized combination of medications and outpatient interventional procedures (targeted nerve blocks, minimally invasive treatments that reduce nerve irritation). In many cases, this approach allows surgery to be avoided entirely.

Supportive therapy using appropriately selected vitamins, minerals, and supplements may help nerve recovery. The selection is not universal; it is tailored to the type of nerve irritation and laboratory findings.

Image: Interventional pain procedure used in trigeminal neuralgia treatment

Surgical treatment of typical trigeminal neuralgia: When and Why It’s Needed

This procedure involves a small opening in the skull behind the ear (craniotomy) and gently separating the blood vessel from the trigeminal nerve. A small Teflon pad is then placed between them to prevent further pulsatile compression.. It has excellent long-term results: more than 75–90% of patients achieve immediate pain relief, and about 70–80% maintain significant improvement in the long term.
MVD is the most effective treatment for classical / Type 1 trigeminal neuralgia (paroxysmal, shock-like pain).
This does not apply to more atypical trigeminal neuralgia (when the pain is continuous and characterized by burning/aching, the patient is younger than 60, and no vascular compression is seen), where surgical success rates are significantly lower.

The procedure lasts about 2 hours and is generally well tolerated, even in patients older than 70 who are in good overall condition.

Minimally invasive and non-invasive options for trigeminal neuralgia when open surgery isn’t ideal

For patients who are not candidates for open surgery or general anesthesia, a percutaneous trigeminal rhizotomy may be used—a needle procedure through the cheek to the Gasserian ganglion (the nerve cluster where trigeminal branches converge at the skull base). The main techniques are radiofrequency rhizotomy (creating a brief heat lesion), balloon compression, and, less commonly today, glycerol rhizolysis. These procedures are performed under short sedation, usually provide rapid pain relief in typical trigeminal neuralgia, and can be repeated if pain recurs. The trade-off is a higher likelihood of facial numbness; when V1 (the eye branch) is involved, the corneal (blink) reflex is carefully protected. The aim is to preferentially interrupt pain-carrying fibers while preserving normal facial sensation and motor function, but selectivity is imperfect, so some numbness or dysesthesia can still occur.

Gamma Knife radiosurgery is a non-invasive treatment option. Focused radiation is directed at the trigeminal nerve where it enters the brainstem (root entry zone), and in some centers slightly farther along the nerve (retrogasserian/cisternal segment). The goal is to reduce pain signal transmission while preserving normal facial sensation and muscle function. Despite precise targeting, some patients may still experience facial numbness.

Pain relief develops gradually — over several weeks to a few months.

Compared with percutaneous rhizotomy (balloon compression, glycerol, or radiofrequency), sensory side effects are less frequent after Gamma Knife (approximately 10–30% vs. 40–80%, depending on the technique and series). Long-term pain-free rates at around 5 years generally range from 40–60%.

Gamma Knife can be repeated if pain returns, but usually no more than 1–2 times in a lifetime due to cumulative radiation exposure. Percutaneous rhizotomy procedures can be repeated multiple times if necessary.

When choosing between Gamma Knife and percutaneous rhizotomy, a common approach is to start with Gamma Knife when a gradual onset of relief over 2–6 months is acceptable and a lower risk of permanent facial numbness is a priority. If pain is severe and uncontrolled despite medications—or if Gamma Knife does not provide adequate relief after an appropriate waiting period—percutaneous rhizotomy offers fast control (often within 24–48 hours) with a higher likelihood of numbness. The choice ultimately depends on the urgency of pain relief, comorbidities, imaging, and patient priorities regarding the risk–benefit balance of each method.

Peripheral nerve blocks are a minimally invasive option used when medications are not sufficient or when diagnostic clarification is needed. A small amount of anesthetic, sometimes combined with an anti-inflammatory medication, is injected around the trigeminal nerve branch or trigger zone to interrupt the pain cycle and confirm the source of pain. Depending on the clinical scenario, the block may target a superficial cutaneous branch (supraorbital, infraorbital, mental nerve) or a deeper segment of the trigeminal nerve (V2/V3). Deep, complex blocks include the maxillary nerve block (V2) in the pterygopalatine fossa, mandibular nerve block (V3) near the foramen ovale, or pterygopalatine ganglion block when pain radiates behind the eye or into the palate. These deeper procedures are performed under ultrasound or fluoroscopic guidance to safely navigate structures that are only millimeters wide and surrounded by major vessels and nerves. Relief is often immediate and may last from several days to several months; in many patients, one to three sessions combined with optimized medication are enough for long-term pain control.

Botulinum toxin (Botox) injections can be used as an adjunct therapy in patients who do not tolerate medications well or whose pain persists despite drug treatment. Botox is injected subcutaneously or intradermally along the painful dermatome, directly over the sensitive trigger zones or along the course of the affected trigeminal branch (most often V1, V2, or V3). By acting on the peripheral endings of sensory nerve fibers, Botox reduces the release of pain-transmitting neuropeptides, lowers nerve hypersensitivity, and decreases the frequency and intensity of pain attacks. Clinical studies and experience show that some patients feel significant improvement within 7–14 days after injection, particularly those with constant burning or aching facial pain. Botox does not damage the nerve and does not interfere with future surgical or interventional options. It can be repeated every 3–6 months if needed, and it is particularly useful in atypical trigeminal neuralgia and post-herpetic trigeminal pain.

Neuromodulation (nerve stimulation) is reserved for rare, treatment-resistant cases where medications, blocks, and standard procedures have not provided adequate relief. A small stimulator (similar to a pacemaker) is implanted to deliver electrical impulses to the trigeminal nerve (Gasserian ganglion) or its branches. These impulses modify how the nerve transmits pain signals to the brain. Although neuromodulation is not a first-line treatment, it can be highly effective in carefully selected patients. In some centers, temporary external stimulation is performed first to evaluate response before permanent implantation is considered. In very select, treatment-resistant cases, deep brain stimulation (targeting specific regions of the thalamus) or motor cortex stimulation (placing electrodes on the surface of the brain over the motor cortex) has been investigated as a neuromodulation option. These approaches are rarely performed and remain experimental.

Peripheral neurectomy (“nerve pulling”) / thermal or chemical neurolysis of terminal trigeminal branches has a very limited role today. It may deliver short-term relief in highly selected cases (e.g., very elderly or those with major comorbidity, or a rare, well-localized peripheral trigger), but recurrence is common and there is a meaningful risk of anesthesia dolorosa (painful numbness). For these reasons it is generally avoided when other effective options (optimized medication, percutaneous rhizotomy, or Gamma Knife) are available.

These methods work best for typical (paroxysmal) TN. In patients with continuous/atypical facial pain, results are less predictable, so therapy is individualized and often begins with an optimized medication plan (dosing, combinations, sequencing). The key is to identify the exact pain generator—for example a peripheral trigger point, scar, focal nerve entrapment or a neurovascular contact—and, when appropriate, perform targeted interventions directly at that site (e.g., selective nerve blocks, trigger-point injections or very small, focused ablations).

Atypical Trigeminal Neuralgia: Difference Between Typical and Atypical Trigeminal Neuralgia

Atypical trigeminal neuralgia represents a different clinical group, as the standard treatment protocol used for classical TN often fails. Consequently, these patients respond poorly to microvascular decompression (MVD) and achieve significantly lower success rates than typical TN from radiation procedures such as Gamma Knife.

In addition to the sudden, sharp paroxysmal attacks, patients often experience a persistent background pain between episodes, which is typically described as a continuous burning, aching, or throbbing sensation.

Clinical clues suggesting atypical TN include: weak or short-lived response to carbamazepine (Tegretol), younger age of onset, gradual onset instead of sudden attacks, persistent pain without pain-free intervals, pain beginning after dental procedures, pain provoked by chewing or talking, and absence of vascular compression on MRI.

In these patients, the cause is usually not a blood vessel compressing the trigeminal nerve at the brainstem, but irritation of the nerve somewhere along its course in the face. Irritants can have different locations and different types. These types include: inflammation of nearby tissues, spasms, vascular compression by facial arteries, scarring, infection, etc. The key is to locate the exact point of irritation through a detailed conversation and functional pain testing during a video consultation. Without identifying the source of irritation, treatment becomes guesswork and often fails.

Some authors use the terms trigeminal neuralgia type 1 (TN1), which mostly describes the typical paroxysmal form, and type 2 (TN2) to describe the constant pain form. The problem with this terminology is that TN2 simply groups together all cases that are not TN1, even though these patients may have completely different causes of nerve irritation. In other words, TN2 describes how the pain feels, but not why it exists. On this page, we use a more practical classification based on the actual cause of nerve irritation, because treatment depends on the mechanism, not on the label.

Viral Injury of the Trigeminal Nerve

In some patients, trigeminal pain does not come from vascular compression at the nerve root or from local irritations in the face, but from viral injury of the nerve itself. This most commonly occurs after a shingles infection affecting the trigeminal nerve (postherpetic neuralgia), or after recurrent oral herpes caused by herpes simplex virus (HSV-1). Both viruses can remain dormant in the trigeminal ganglion and, when reactivated, sensitize or inflame a single branch of the nerve—causing burning, hypersensitivity, or electric pain along a specific area of the face. In these cases, the problem is not a blood vessel pressing on the nerve but damage or inflammation of the nerve fibers, and treatment follows the principles of neuropathic pain management. During the infection, local irritative sources in the face (spasm, inflammation of local tissue) also appear. When symptoms clearly follow herpes outbreaks, antiviral suppression may also be considered.

How Atypical Trigeminal Neuralgia Is Treated When Standard Therapies Fail

When the specific process and location causing irritation of the trigeminal nerve are accurately identified, targeted treatment can be implemented. In everyday practice, however, this is often not determined precisely enough, and treatment fails as a result. In such cases, the failure is frequently blamed on the patient’s age, psychological factors, or other chronic illnesses. While these factors may contribute to the overall condition, they are not an excuse for not achieving successful treatment.

Once the type and exact location of nerve irritation are identified, an appropriate combination of medications is prescribed. The goal is to significantly reduce the pain within 10 days, even if the pain has been present for a long time. If a pain-free state can be maintained for 6 to 8 weeks, the therapeutic effect is usually long-lasting. When all contributing sources of irritation are recognized, most cases improve with a targeted combination of medications addressing every underlying mechanism, supported by vitamin and supplement therapy. These medications must be adjusted in type and dosage over a period of 6–8 weeks. Previous medication failure does not always mean that medication cannot help. In many persistent cases, the problem is that the right combination of mechanisms was not treated together—but it should be. In most cases, a special intervention is not needed to reduce pain.

This outcome can also be achieved through online consultations via messages and video calls. It is particularly important that the doctor is available during the first ten days of treatment so that medication type or dosage can be adjusted quickly if needed. Thanks to telehealth, top specialists are accessible even when the patient is not in the same city.

A physical examination is not necessary; what matters is that a specialist who understands pain anatomy conducts the consultation and asks the right questions (either in person or via video call). During the consultation, the doctor instructs the patient to perform specific jaw and neck movements or apply pressure to certain areas to provoke or relieve the pain. This has the same diagnostic value as an in-person examination. Most patients have never had such testing performed. Usually, one to three video consultations are enough to achieve long-term pain relief.

In some cases, drug therapy alone is not sufficient to treat trigeminal neuralgia, and interventional methods are required. These methods include precise injection of medication directly into the process causing nerve irritation and pain, or the use of other interventional techniques such as stimulation, heating, lesioning, or decompression.

Because pain sources are usually very small — often less than 1 cm — and located deep within the tissue surrounded by important structures, the procedure must be performed under imaging guidance. The insertion of the needle is guided by ultrasound or fluoroscopy to ensure accurate delivery of the medication.

If an interventional procedure is being considered, medication preparation is required beforehand, which can be prescribed after an in-person or online video consultation. Very often, once medication preparation begins, the need for a procedure disappears — meaning that properly selected medication therapy alone can resolve the pain.

These procedures are performed on an outpatient basis (sometimes even at home), are not painful, and pain relief is immediate. The entire process, including the examination, typically takes 1 to 1.5 hours, after which the patient can return home. For long-term effect, 1 to 3 interventional procedures are usually required, spaced a few weeks apart.

If these procedures do not achieve sufficient relief, additional methods such as Gasserian ganglion lesioning or Gamma Knife radiosurgery can be performed.

Summary: In the vast majority of patients with persistent and intense facial pain, the pain can be stopped and controlled with modern medication therapy, or — in more severe cases — with special outpatient or in-home interventional procedures. Because of their high success rate, this treatment should always be attempted before surgical procedures or stereotactic radiation (Gamma Knife).

Why Trigeminal Neuralgia Pain Persists Despite Treatment

In many patients, trigeminal neuralgia persists despite medication or procedures not because the condition is untreatable, but because the exact mechanism and location of nerve irritation have not been precisely identified. Standard therapies are often applied based on the general diagnosis, without clearly determining which anatomical structure is responsible for the pain, what pathological process is occurring within that structure, and which contributing factors are maintaining the pain — and it is precisely this failure to identify all three that leads to persistent pain despite treatment.

In many patients, pain persists even when medications such as carbamazepine or other standard therapies initially provide relief, or stop working over time.

Another common reason is that treatment addresses only one aspect of the problem. For example, medication may reduce nerve excitability, but ongoing mechanical or vascular irritation continues to trigger pain. In other cases, procedures are performed without fully understanding all contributing factors, leading to only temporary or incomplete relief.

In long-standing cases, the nervous system itself can become sensitized, meaning that even minor stimuli can provoke severe pain. This does not mean that the condition is psychological, but rather that multiple mechanisms are interacting and maintaining the pain.

For this reason, when trigeminal neuralgia does not improve, the key step is not simply repeating the same treatments, but performing a structured reassessment to identify all active pain mechanisms. Only after this analysis can treatment be adjusted in a targeted and effective way.

Treatment of Contributing Factors in Atypical Trigeminal Neuralgia

Effective treatment of atypical trigeminal neuralgia always begins with identifying the primary pain generator — whether the dominant source of symptoms is trigeminal nerve dysfunction,local irritation, post-traumatic or post-dental nerve injury, central pain processing changes, or a combination of these mechanisms.

However, in many patients, pain persists not only because of the primary cause, but because additional contributing factors are not recognized or adequately addressed. These factors rarely act as the sole cause of pain, but they can maintain nerve irritation, increase pain sensitivity, delay recovery, and reduce the effectiveness of otherwise appropriate treatment.

For that reason, successful management requires not only identifying the dominant neurological irritation but also understanding the broader mechanical, neurological, and systemic context in which the pain persists.

What contributing factors may play a role in atypical trigeminal neuralgia?

• Previous dental or surgical procedures — Tooth extractions, root canal treatments, implants, or facial surgeries may lead to nerve irritation or altered signaling, even when the procedure was technically correct.
• Chronic peripheral nerve irritation — Persistent irritation of trigeminal branches (infraorbital, mental, alveolar nerves) can maintain ongoing pain even without clear structural compression.
• Central sensitization — The nervous system becomes more sensitive over time, amplifying signals and leading to constant, burning, or diffuse pain typical for atypical trigeminal neuralgia.
• Muscle tension and myofascial factors — Increased tension in masseter, temporalis, and cervical muscles may contribute to altered pain perception and overlapping pain patterns.
• Temporomandibular joint (TMJ) dysfunction — Abnormal jaw mechanics, bruxism, or joint irritation can maintain persistent facial pain.
• Repetitive microtrauma and parafunctional habits — Teeth clenching, grinding, or repetitive jaw activity can maintain trigeminal irritation.
• Metabolic factors, pro-inflammatory diet and low-grade inflammation — Obesity, insulin resistance, chronic inflammation, and processed/high-sugar diet increase pain sensitivity and slow recovery.
• Nutritional deficiencies — Low levels of vitamin D, vitamin B12, magnesium, or iron may contribute to nerve dysfunction and impaired healing.
• Vitamin-related factors — Both deficiency and excess of vitamin B6 may contribute to burning pain, tingling, or hypersensitivity.
• Sleep disturbances and autonomic dysregulation — Poor sleep increases pain sensitivity and reduces pain tolerance.
• Stress and persistent pain-related vigilance — Stress increases central nervous system reactivity and amplifies pain perception.
• Medications and previous treatments — Long-term use of pain medications, repeated ineffective treatments, or certain drugs (such as statins in some patients, which may be associated with muscle-related symptoms) may alter pain perception or contribute to persistent symptoms without resolving the underlying mechanism.
• Other medical conditions and comorbidities — Autoimmune diseases, diabetes, thyroid disorders, and chronic inflammatory states increase nerve sensitivity and reduce treatment response.
• Psychophysical interaction (not psychological cause) — Chronic pain changes central processing of pain signals; this does not mean the pain is psychological, but that the system has become more reactive.

Why this matters in practice

In many cases, treatment fails because the primary pain generator is not correctly identified, and therapy is directed only at one part of the problem — most often a single medication alone or repeated dental procedures.

Conversely, even when the main neurological cause is recognized, failure to address contributing factors often leads to only partial or temporary improvement.

The most effective approach is a carefully selected combination of treatment that addresses both the dominant pain mechanism and all relevant contributing factors. An incomplete approach — even when it includes individually effective methods — is one of the most common reasons why atypical trigeminal neuralgia becomes persistent.

In practice, many patients try to address parts of this problem on their own — through diet changes, supplements (vitamin D, magnesium), physiotherapy, or different medications. While these approaches can be helpful, they rarely lead to lasting improvement if the primary pain mechanism is not clearly identified and treated. On the other hand, even well-targeted medical treatment may fail if all contributing factors are not recognized and corrected.

Many patients reading this recognize that they have already tried one part of this approach — but not the complete strategy. This is one of the most common reasons why atypical trigeminal neuralgia becomes chronic.

Prognosis of Trigeminal Neuralgia

Typical (Classical) Trigeminal Neuralgia

In typical TN, especially when MRI confirms vascular compression at the root entry zone of the trigeminal nerve, the prognosis is generally favorable. About 70–80% of patients experience significant pain reduction with first-line medications (carbamazepine or oxcarbazepine). However, because of side effects or decreased effectiveness over time, only about 30–40% remain well-controlled by medications alone in the long term. When pain persists or medications are poorly tolerated, interventional or surgical treatments are considered. Microvascular decompression (MVD) offers the highest long-term success rate, with approximately 70–85% of patients remaining pain-free for years. Gamma Knife radiosurgery and percutaneous rhizotomy also provide excellent short-term relief (70–90%), although durability is generally lower than with MVD. Overall, in typical TN, around one-third of patients achieve sustained relief with medications alone, while two-thirds will eventually require a procedure such as MVD, radiosurgery, or a minimally invasive percutaneous technique.

Atypical (Constant Pain / Non-Classical) Trigeminal Neuralgia

The prognosis for atypical TN is different because the pain mechanism is not caused by classical vascular compression. Triggers may include peripheral irritation in the face, scarring, inflammation, infection (post-herpetic or HSV-related), or irritation of smaller nerve branches. Medication success is lower than in typical TN — only about 30–50% of patients achieve meaningful improvement with medications alone, and sustained long-term control with drugs only is achieved in roughly 20–30%. These patients usually require a targeted combination of medications and, when needed, interventional procedures that focus on the exact site of irritation (ultrasound-guided blocks, radiofrequency of peripheral branches, or botulinum therapy). Gamma Knife and Gasserian ganglion lesion are also indicated when medications and targeted nerve blocks are not successful, but long-term success rates are lower when there is no vascular compression and the pain is continuous (atypical form).

Online pain consultation for trigeminal neuralgia in detail

Schematic explanation of the video consultation for trigeminal neuralgia

Answers to questions about the process and success of video consultations for trigeminal neuralgia

See the page “Possible Reasons for Poor Pain Treatment Effectiveness of Trigeminal Neuralgia” for an explanation of why conventional chronic pain treatments often fail—and what we do differently.

Treatment of complex cases of trigeminal neuralgia can be analysed by artificial intelligence (AI)

Video consultation is also known as a virtual visit, video visit, online consultation, remote consultation or telehealth appointment.

Before contacting us, please read our Privacy Policy and Terms of Use.

Frequently Asked Questions About Trigeminal Neuralgia

Related Resources on Trigeminal Neuralgia and Facial Pain

Trigeminal Neuralgia

Treatment of Trigeminal Neuralgia

Atypical Trigeminal Neuralgia

Nerosurgery & Pain Treatment

You can read about the various forms of primary and secondary headaches on this page.